Breakthrough Therapy Designation

Breakthrough Therapy Designation designates an FDA programme providing intensive guidance and accelerated development assistance for drugs treating serious conditions where preliminary clinical evidence demonstrates substantial improvement over existing therapies on a clinically significant endpoint, enabling more frequent interactions with FDA and rolling review of completed application sections.

The biopharmaceutical industry pursues Breakthrough Therapy Designation as a strategic regulatory milestone providing competitive advantages through accelerated development timelines and enhanced FDA engagement. Designation enables cross-disciplinary senior FDA staff involvement in drug development from early stages, guidance on efficient development programme design, and rolling review allowing submission and review of completed sections before the full application is submitted. Preliminary clinical evidence from early trials may qualify if showing remarkable effects on meaningful endpoints in diseases with unmet needs. Annual reports on designated programmes are required. As the programme has matured since 2012, Breakthrough Therapy Designation has become an important development accelerator enabling faster access to potentially transformative medicines for patients with serious unmet needs.